259217-95-3

Usage

Uses

Used in Pharmaceutical Industry:
Cyclopropanecarboxylic acid, 1-[[(1,1-dimethylethoxy)carbonyl]amino]-2-ethenyl-, ethyl ester, (1R,2S)is used as an intermediate in the biosynthetic preparation of several hepatitis C inhibitors. Its unique structure and functional groups make it a valuable building block for the development of antiviral drugs targeting the hepatitis C virus.
In the pharmaceutical industry, Cyclopropanecarboxylic acid, 1-[[(1,1-dimethylethoxy)carbonyl]amino]-2-ethenyl-, ethyl ester, (1R,2S)- plays a crucial role in the synthesis of drugs that can effectively combat hepatitis C, a viral infection that affects the liver and can lead to severe health complications if left untreated. Cyclopropanecarboxylic acid, 1-[[(1,1-dimethylethoxy)carbonyl]amino]-2-ethenyl-, ethyl ester, (1R,2S)-'s specific stereochemistry and functional groups enable the design of inhibitors that can target and disrupt the life cycle of the hepatitis C virus, thereby helping to control the infection and alleviate symptoms in affected individuals.

InChI:O=C(OCC)[C@]1(NC(=O)OC(C)(C)C)[C@H](\C=C)C1

Upstream product

• 213316-49-5 (1RS,2SR)-ethyl 2-vinyl-1-(tert-butoxycarbonylamino)cyclopropanecarboxylate 
• 681807-59-0 (1R,2S)-ethyl 1-(tert-butoxycarbonylamino)-2-vinylcyclopropanecarboxylate 
• 259214-54-5 (trans)-ethyl 1-amino-2-vinylcyclopropanecarboxylate hydrochloride 
• 787548-29-2 (1R,2S)/(1S,2R) 1-amino-2-vinylcyclopropane carboxylic acid ethyl ester 
• 24424-99-5 di-tert-butyl dicarbonate 
• 1393095-18-5 (E)-ethyl 1-(benzylideneamino)-2-vinylcyclopropanecarboxylate 
• 1023795-84-7 C₂₁H₂₁NO₂ 
• 213316-32-6 rac-(1R,2S)-1-amino-2-vinylcyclopropanecarboxylic acid ethyl ester 
• 681807-60-3 (1R,2S)-ethyl 1-amino-2-vinylcyclopropanecarboxylate hydrochloride 
• 1159609-95-6 (1R,2S)-1-amino-2-vinylcyclopropanecarboxylic acid ethyl ester tosylate salt 

Downstream Products

• 259214-54-5 ethyl (1R,2S)-1-amino-2-vinylcyclopropanecarboxylate hydrochloride 
• 746657-36-3 (1R,2S)-ethyl 1-amino-2-vinylcyclopropanecarboxylate 
• 259214-54-5 ethyl (1S,2R)-1-amino-2-vinylcyclopropanecarboxylate hydrochloride 
• 630421-48-6 tert-butyl ((1R,2S)-1-{[(cyclopropylsulfonyl)amino]carbonyl}-2-vinylcyclopropyl)carbamate 
• 1279037-85-2 (1R,2R)-1-(tert-butoxycarbonylamino)-2-vinyl-cyclopropane-1-carboxylic acid 
• 862119-82-2 (2S,4R)-tert-butyl 2-((1R,2S)-1-(ethoxycarbonyl)-2-vinylcyclopropylcarbamoyl)-4-hydroxypyrrolidine-1-carboxylate 
• 862119-83-3 (1R,2S)-1-[(2S,4R)-(4-hydroxy-pyrrolidine-2-carbonyl)-amino]-2-vinyl-cyclopropanecarboxylic acid ethyl ester 
• 552335-44-1 (1R,2S)-ethyl 1-((2S,4R)-1-((S)-2-(((tert-butoxy)carbonyl)amino)non-8-enoyl)-4-hydroxypyrrolidine-2-carboxamido)-2-vinylcyclopropanecarboxylate 
• 923591-34-8 tert-butyl ((1R,2R)-1-{[(cyclopropylsulfonyl)amino]carbonyl}-2-ethylcyclopropyl)carbamate 
• 1152134-45-6 (1R,2R)-1-(tert-butoxycarbonylamino)-2-(difluoromethyl)cyclopropanecarboxylic acid 
• 1360828-80-3 C₉H₁₄F₂N₂O₃S*ClH 
• 772337-53-8 (1R,2S)-1-amino-N-(cyclopropylsulfonyl)-2-vinylcyclopropane-1-carboxamide 
• 790305-05-4 tert-butyl (2R,6S,13aS,14aR,16aS,Z)-14a-(cyclopropylsulfonylcarbamoyl)-2-hydroxy-5,16-dioxo-1,2,3,5,6,7,8, 9,10,11,13a,14,14a,15,16,16a-hexadecahydronaphthylcyclopropanoyl[e]pyrrolo[1,2-a][1,4]diazacyclopenta decyne-6-yl-carbamate 
• 924305-02-2 (1R,2S)-ethyl 1-((2S,4R)-4-hydroxypyrrolidine-2-carboxamido)-2-vinylcyclopropanecarboxylate hydrochloride 

Relevant academic research and scientific papers

CALPAIN MODULATORS AND METHODS OF PRODUCTION AND USE THEREOF

The present technology relates to compounds, kits, compositions, and methods useful for the treatment of fibrotic disease. In some aspects, the present technology provides for treatment of various diseases or disorders associated or mediated, at least in part, by calpains, such as CAPN1, CAPN2, and/or CAPN9. The present technology is generally applicable to compounds which inhibit myofibroblast differentiation.

Class of large ring heterocyclic compound restraining HCV and manufacturing and uses thereof

The invention relates to a class of compounds that inhibit HCV. The compounds are represented by Formula A. The invention also relates to preparation and pharmaceutical use of the compounds.

Macrocyclic compounds for suppressing replication of hepatitis C virus

A compound as represented by Formula (I) is provided, wherein groups are defined in the description. The compound is used as HCV protease inhibitor for treating HCV infection.

Hepatitis C Virus Inhibitors

Hepatitis C virus inhibitors having the general formula are disclosed. Compositions comprising the compounds and methods for using the compounds to inhibit HCV are also disclosed.

Inhibitors of Hepatitis C Virus

Macrocyclic peptides are disclosed having the general formula: wherein R3, R′3, R4, R6, R′, X, Q and W are described. Compositions comprising the compounds and methods for using the compounds to inhibit HCV are also disclosed.

MACROCYCLIC PEPTIDES AS HEPATITIS C VIRUS INHIBITORS

Macrocyclic peptides having the general formula are disclosed. Compositions comprising the compounds and methods for using the compounds to inhibit HCV are also disclosed.

Inhibitors of Hepatitis C Virus

Macrocyclic peptides are disclosed having the general formula: wherein R3, R3′, R4, R6, R′, X, Q and W are described. Compositions comprising the compounds and methods for using the compounds to inhibit HCV are also disclosed.

Hepatitis C Virus Inhibitors

Hepatitis C virus inhibitors having the general formula are disclosed. Compositions comprising the compounds and methods for using the compounds to inhibit HCV are also disclosed.

MACROCYCLIC PEPTIDES AS HEPATITIS C VIRUS INHIBITORS

Macrocyclic peptides having the general formula (I): are disclosed. Compositions comprising the compounds and methods for using the compounds to inhibit HCV are also disclosed.

Hepatitis C Virus Inhibitors

Hepatitis C virus inhibitors having the general formula are disclosed. Compositions comprising the compounds and methods for using the compounds to inhibit HCV are also disclosed.